

editing of the manuscript; collection, analysis, and interpretation of data; critical review of the manuscript.

Mahony Santana: Approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; critical review of the manuscript.

Celina Leite: Approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; critical review of the manuscript;

## Conflicts of interest

None declared.

## References

1. Aoki V, Rivitti EA, Diaz LA, Cooperative Group on Fogo Selvagem Research. Update on fogo selvagem, an endemic form of pemphigus foliaceus. *J Dermatol.* 2015;42:18–26.
2. Hans-Filho G, Aoki V, Bittner NRH, Bittner GC. Fogo selvagem: endemic pemphigus foliaceus. *An Bras Dermatol.* 2018;93:638–50.
3. Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. *J Am Acad Dermatol.* 2009;60:595–603.
4. Porro AM, Hans Filho G, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus – Brazilian Society of Dermatology. *An Bras Dermatol.* 2019;94:20–32.
5. Teixeira TA, Fiori FC, Silvestre MC, Borges CB, Maciel VG, Costa MB. Refractory endemic pemphigus foliaceus in adolescence successfully treated with intravenous immunoglobulin. *An Bras Dermatol.* 2011;86:S133–6.

Hiram Larangeira de Almeida Jr. <sup>a,b,\*</sup>,  
Junior Wiczorek <sup>a</sup>, Mahony Santana <sup>b</sup>,  
Celina Leite <sup>c</sup>

<sup>a</sup> Postgraduate Program in Health and Behavior, Universidade Católica de Pelotas, Pelotas, RS, Brazil

<sup>b</sup> Department of Dermatology, Universidade Federal de Pelotas, Pelotas, RS, Brazil

<sup>c</sup> Faculty of Medicine, Universidade Católica de Pelotas, Pelotas, RS, Brazil

\* Corresponding author.

E-mail: [hiramalmeidajr@hotmail.com](mailto:hiramalmeidajr@hotmail.com) (H.L. Almeida Jr.).

Received 9 March 2022; accepted 24 May 2022

Available online 22 September 2023

<https://doi.org/10.1016/j.abd.2022.05.013>

0365-0596/ © 2023 Sociedade Brasileira de Dermatologia.

Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

## Unresectable auricular squamous cell carcinoma with locoregional metastasis: use of cemiplimab in an immunosuppressed patient\*



Dear Editor,

An 81-year-old male agricultural worker, with hypertension complicated with nephropathy and renal transplantation in 2005, using sirolimus, was submitted to radiotherapy and hormone blockade therapy in 2017 for prostate cancer. He had a past history of multiple basal cell carcinomas and squamous cell carcinomas (SCCs). He developed a moderately differentiated, ulcerated, and infiltrating SCC in the right auricular pinna (Fig. 1A), considered unresectable due to recurrence after four surgical interventions, with involvement of the perichondrium, cervical lymph nodes, and salivary glands, demonstrated by anatomopathological examination. Screening for distant metastasis through PET-CT was negative, and he was classified as T3N2bM1. He received intravenous cemiplimab, 350 mg every 21 days, and 20 sessions of radiotherapy (RT), 20 fractions of 250 cGy, a total dose of 50 Gy, in the tumor and auricular pinna, with

complete involution of the neoplasm and regional involvement in four months (Fig. 1B), evaluated clinically and through a second PET-CT. There were no adverse effects to the medication. He evolved with progression of the prostate cancer, confirmed by anatomopathological examination, and died 14 months after the use of cemiplimab.

Around 5% of SCCs are classified as advanced neoplasia when they present as locally advanced or metastatic and not amenable to curative surgery and/or curative radiotherapy.<sup>1,2</sup> Until recently, chemotherapy and epidermal growth factor receptor inhibitors were the only options available for these cases, with low efficacy, nonsustained response rates, and various side effects, being considered palliative treatments.<sup>1</sup>

Cemiplimab is the first approved systemic treatment for SCC that improves survival. This is a fully human anti-PD-1 IgG4 antibody.<sup>3</sup> An indirect comparison of treatments concluded that it is the systemic therapy with the strongest evidence of clinical benefit for advanced cases and improved survival.<sup>4</sup>

The high mutation burden present in SCCs from exposure to ultraviolet radiation has been associated with the effectiveness of PD-1 inhibition in several advanced solid neoplasms.<sup>1,2</sup> Furthermore, the strong association between immunosuppression and tumor risk has suggested that immunosurveillance plays an important role in tumor control, and approaches to enhance the anti-tumor immune system may be effective.<sup>1</sup>

\* Study conducted at the Hospital Mater Dei, Belo Horizonte, MG, Brazil.



**Figure 1** (A) Extensive tumor affecting the auricular pinna and adjacent structures. (B) Cicatricial lesion on the pinna after four months using cemiplimab.

PD-1 is a transmembrane inhibitory protein present in immune cells, and blocking it increases the anti-tumor activity of T-cells, promoting immunological control and the death of cancer cells.<sup>3</sup>

It is not possible to precisely determine the isolated effect of the PD-1 inhibitor in the case described herein, due to the concomitant use of RT. However, there was resolution of enlarged cervical lymph nodes that were not irradiated, possibly due to the medication effect. In phase 2 studies with patients with locally advanced SCC, 55% of them also underwent radiotherapy prior to starting the medication.<sup>1</sup>

The advent of new drugs for the treatment of cutaneous neoplasms has shown promising results, with evidence of clinically significant effects, acceptable safety, and tolerability profile in patients with advanced SCC who are not candidates for surgery or RT.<sup>5</sup> Long-term studies including immunosuppressed patients are required to assess the outcomes in these patients and to determine the efficacy and side effects of cemiplimab in this population.

### Financial support

None declared.

### Authors' contributions

Tatiana Ferreira França: Drafting and editing of the manuscript; critical review of important intellectual content and approval of the final version of the manuscript.

João Renato Vianna Gontijo: Intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; drafting and editing of the manuscript; critical review of important intellectual content and approval of the final version of the manuscript.

Eduardo Ferraz Veloso Junior: Intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; drafting and editing of the manuscript; critical review of important intellectual content and approval of the final version of the manuscript.

Enaldo Melo de Lima: Intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; drafting and editing of the manuscript; critical review of important intellectual content and approval of the final version of the manuscript.





### Conflicts of interest

None declared.

### References

1. Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. *Lancet Oncol.* 2020;21:294–305.
2. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. *N Engl J Med.* 2018;379:341–51.
3. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. *Cancers (Basel).* 2020;12:738.
4. Keeping S, Xu Y, Chen CI, Cope S, Mojebi A, Kuznik A, et al. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma. *Future Oncol.* 2021;17:611–27.
5. Baggi A, Quaglino P, Rubatto M, Depenni R, Guida M, Ascierto PA, et al. Real world data of cemiplimab in locally advanced and

metastatic cutaneous squamous cell carcinoma. *Eur J Cancer*. 2021;157:250–8.

Tatiana Ferreira França <sup>a</sup>,  
João Renato Vianna Gontijo <sup>a,b,\*</sup>,  
Eduardo Ferraz Veloso Junior <sup>b</sup>,  
Enaldo Melo de Lima <sup>b</sup>

<sup>a</sup> *Dermatology Unity, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil*  
<sup>b</sup> *Hospital Mater Dei, Belo Horizonte, MG, Brazil*

\* Corresponding author.

*E-mail:* [joaorenatogontijo@gmail.com](mailto:joaorenatogontijo@gmail.com) (J.R. Gontijo).

Received 6 October 2022; accepted 29 December 2022

Available online 29 August 2023

<https://doi.org/10.1016/j.abd.2022.12.008>

0365-0596/ © 2023 Sociedade Brasileira de Dermatologia.

Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).